Prosecution Insights
Last updated: October 02, 2026
Application No. 17/789,113

METHOD FOR MANUFACTURING 1,3-BUTYLENE GLYCOL, AND 1,3-BUTYLENE GLYCOL PRODUCT

Non-Final OA §DOUBLEPATENT
Filed
Jun 24, 2022
Priority
Dec 28, 2019 — JP 2019-239974 +8 more
Examiner
KIFLE, BRUCK
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Daicel Corporation
OA Round
2 (Non-Final)
79%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
1377 granted / 1738 resolved
+19.2% vs TC avg
Strong +16% interview lift
Without
With
+15.9%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 10m
Avg Prosecution
48 currently pending
Career history
1754
Total Applications
across all art units

Statute-Specific Performance

§101
5.9%
-34.1% vs TC avg
§103
12.8%
-27.2% vs TC avg
§102
12.2%
-27.8% vs TC avg
§112
53.6%
+13.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1738 resolved cases

Office Action

§DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This application has been transferred to a new Examiner. Applicant’s amendments and remarks filed October 15, 2025 have been received and reviewed. Claims 1-15 and 21-25 are now pending in this application. Double Patenting Claims 1-15 and 21-25 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5, 7-9, 11-14 and 19-20 of copending Application No. 17/788,803 (reference application) in view of Tsuji et al. US 2003/0018224 A1. Claims 1-15 and 21-25 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5 and 7-20 of copending Application No. 17/788,968 (reference application) in view of Tsuji et al. US 2003/0018224 A1. Claims 1-15 and 21-25 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 14-20 of copending Application No. 17/789,067 (reference application) in view of Tsuji et al. US 2003/0018224 A1. Claims 1-15 and 21-25 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-14 and 21 of copending Application No. 17/789,087 (reference application) in view of Tsuji et al. US 2003/0018224 A1. Claims 1-11 and 21-25 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4 and 6-9 of copending Application No. 17/789,093 (reference application). Claims 1-15 and 21-25 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of copending Application No. 17/788,991 (reference application) in view of Tsuji et al. US 2003/0018224 A1. The basis of these rejection is the same as given in the previous officer action and is incorporated herein fully by reference. Applicants have not addressed these rejections. These are provisional nonstatutory double patenting rejections because the patentably indistinct claims have not in fact been patented. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRUCK KIFLE whose telephone number is (571)272-0668. The examiner can normally be reached 8 AM - 6 PM, M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. May 28, 2026 /BRUCK KIFLE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jun 24, 2022
Application Filed
Jul 15, 2025
Non-Final Rejection mailed — §DOUBLEPATENT
Oct 15, 2025
Response Filed
Jun 02, 2026
Final Rejection mailed — §DOUBLEPATENT
Sep 02, 2026
Response after Non-Final Action
Sep 02, 2026
Interview Requested
Sep 15, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12741962
2,3-DISUBSTITUTED PYRIDO[3,4-B]PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS
3y 9m to grant Granted Sep 22, 2026
Patent 12735429
CRYSTAL OF ISOSORBIDE-BIS(TRIMELLITATE ANHYDRIDE) AND METHOD FOR PRODUCING THE SAME
2y 3m to grant Granted Sep 15, 2026
Patent 12715855
FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES
3y 11m to grant Granted Aug 25, 2026
Patent 12708630
COMBINED THERAPY OF 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND VENETOCLAX
2y 10m to grant Granted Aug 18, 2026
Patent 12703684
MASP-2 INHIBITORS AND METHODS OF USE
2y 2m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
79%
Grant Probability
95%
With Interview (+15.9%)
1y 10m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1738 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month